Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.73 |
| ▸ | HRH1 | P35367 | 4/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.71 |
| ▸ | HTR2C | P28335 | 2/20 | 0.71 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.71 |
| ▸ | HTR7 | P34969 | 1/20 | 0.71 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22561783 | 0.93 | HRH3 (0.74) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| Hydrochloric Acid SCHEMBL10503404 | 0.91 | SIGMAR1 (0.66) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| SCHEMBL10502864 | 0.90 | SIGMAR1 (0.66) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| SCHEMBL18917604 | 0.90 | LTA4H (0.75) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| Hydrochloric Acid SCHEMBL7369873 | 0.90 | HRH3 (0.73) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| Hydrochloric Acid SCHEMBL10503180 | 0.87 | SIGMAR1 (0.62) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| SCHEMBL27689434 | 0.86 | HRH3 (0.71) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| SCHEMBL25809972 | 0.85 | SCN5A (0.68) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| Pitolisant SCHEMBL117648 | 0.85 | HRH3 (1.00) | HRH3HRH1SLC6A2CHRM2ADRA2C | |
| SCHEMBL10504465 | 0.85 | SIGMAR1 (0.62) | HRH3HRH1SLC6A2CHRM2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2594564-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2594562-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015065937-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2010014554-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |